Autolus Therapeutics (AUTL) News Today $1.98 -0.05 (-2.22%) As of 09:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Bank of America Corp DE Reduces Stake in Autolus Therapeutics plc (NASDAQ:AUTL)Bank of America Corp DE reduced its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 82.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,598 shares of the company's stock aftJune 17 at 3:01 AM | marketbeat.comNeedham & Company LLC Reiterates Buy Rating for Autolus Therapeutics (NASDAQ:AUTL)June 14, 2025 | americanbankingnews.comWhat 4 Analyst Ratings Have To Say About Autolus TherapeuticsJune 13, 2025 | benzinga.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Time to Sell?Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down - Should You Sell?June 13, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Autolus Therapeutics (NASDAQ:AUTL)Needham & Company LLC restated a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday.June 12, 2025 | marketbeat.comAutolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) CongressJune 12, 2025 | globenewswire.comAutolus Therapeutics (NASDAQ:AUTL) Trading Down 3.2% - Time to Sell?Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 3.2% - Here's What HappenedJune 11, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Grows Stock Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)Hennion & Walsh Asset Management Inc. raised its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 48.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 386,001 shares of the company's stock aJune 8, 2025 | marketbeat.comAutolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune MarketJune 6, 2025 | seekingalpha.comAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's WhyAutolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's WhyJune 4, 2025 | marketbeat.comAutolus Therapeutics (NASDAQ:AUTL) Shares Up 10% - What's Next?Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 10% - Here's WhyJune 3, 2025 | marketbeat.comTwo Sigma Investments LP Buys 174,485 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Two Sigma Investments LP boosted its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 23.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 906,767 shares of the company's stock after buying an additional 174,485 sharJune 2, 2025 | marketbeat.comWellington Management Group LLP Acquires 1,125,454 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Wellington Management Group LLP grew its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 4.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,345,680 shares of the company's stock after acquiring an additional 1,May 31, 2025 | marketbeat.comMillennium Management LLC Grows Stake in Autolus Therapeutics plc (NASDAQ:AUTL)Millennium Management LLC boosted its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 91.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,653,241 shares of the company's stock after purchMay 31, 2025 | marketbeat.comAutolus Therapeutics to Participate in Upcoming Investor ConferencesMay 29, 2025 | globenewswire.comCetera Investment Advisers Increases Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)Cetera Investment Advisers grew its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 169.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 356,222 shares of the company's stock after buying anMay 26, 2025 | marketbeat.comAutolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute ...May 25, 2025 | morningstar.comAutolus Therapeutics Receives Positive CHMP Opinion for Obecabtagene Autoleucel in Treating Adult Patients with Relapsed or Refractory B-ALLMay 25, 2025 | nasdaq.com247,089 Shares in Autolus Therapeutics plc (NASDAQ:AUTL) Bought by Point72 Asset Management L.P.Point72 Asset Management L.P. purchased a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 247,089 shares of the company's stock, valued at approMay 25, 2025 | marketbeat.comAutolus Therapeutics gets EU endorsement for leukemia treatmentMay 23, 2025 | msn.comAutolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment BrightensMay 23, 2025 | msn.comAutolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)May 23, 2025 | globenewswire.comAutolus Therapeutics plc (AUTL): Analysts See 697% Upside PotentialMay 20, 2025 | insidermonkey.comTFG Asset Management GP Ltd Buys 250,000 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)TFG Asset Management GP Ltd increased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,250,000 shares of theMay 20, 2025 | marketbeat.comAutolus Therapeutics Announces Upcoming Presentations at the European Hematology Association Congress 2025May 17, 2025 | nasdaq.comAutolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) CongressMay 14, 2025 | globenewswire.comAutolus Therapeutics (NASDAQ:AUTL) Issues Quarterly Earnings ResultsAutolus Therapeutics (NASDAQ:AUTL - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02).May 12, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Receives Consensus Rating of "Buy" from AnalystsAutolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) has earned an average recommendation of "Buy" from the six brokerages that are presently covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month price target amonMay 12, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (VCEL), Autolus Therapeutics (AUTL) and Pacira Pharmaceuticals (PCRX)May 11, 2025 | theglobeandmail.comAutolus Therapeutics plc (AUTL) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comAxa S.A. Makes New Investment in Autolus Therapeutics plc (NASDAQ:AUTL)Axa S.A. purchased a new position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,824,685 shares of the company's stock, valued aMay 10, 2025 | marketbeat.comAutolus Therapeutics plc 2025 Q1 - Results - Earnings Call PresentationMay 9, 2025 | seekingalpha.comAutolus Therapeutics PLC (AUTL) Q1 2025 Earnings Call Highlights: Strong US Launch and ...May 9, 2025 | finance.yahoo.comDeep Track Capital LP Cuts Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)Deep Track Capital LP decreased its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 6.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,218,903 shares of the company's stock afterMay 9, 2025 | marketbeat.comAutolus Therapeutics Reports First Quarter 2025 Financial Results and Business UpdatesMay 8, 2025 | globenewswire.comPrice T Rowe Associates Inc. MD Sells 902,261 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Price T Rowe Associates Inc. MD lowered its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,939,241 shares of the company's stock after selling 902,261 sharesMay 6, 2025 | marketbeat.comAutolus Therapeutics (AUTL) Projected to Post Quarterly Earnings on ThursdayAutolus Therapeutics (NASDAQ:AUTL) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-autolus-therapeutics-plc-stock/)May 3, 2025 | marketbeat.comAutolus Therapeutics plc (NASDAQ:AUTL) Stake Boosted by Renaissance Technologies LLCRenaissance Technologies LLC increased its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 146.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 618,942 sharApril 30, 2025 | marketbeat.comLegal & General Group Plc Buys 237,224 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Legal & General Group Plc grew its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 392.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 297,736 shares of the company's stock after buying an additional 237,22April 30, 2025 | marketbeat.comWalleye Capital LLC Trims Stock Position in Autolus Therapeutics plc (NASDAQ:AUTL)Walleye Capital LLC trimmed its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 92.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 75,940 shares of the company's stock after selling 986,453 shares during the period. Walleye Capital LLCApril 29, 2025 | marketbeat.comAutolus Therapeutics’ obecabtagene autoleucel conditionally approved by MHRAApril 27, 2025 | markets.businessinsider.comQ1 Earnings Estimate for AUTL Issued By William BlairAutolus Therapeutics plc (NASDAQ:AUTL - Free Report) - Analysts at William Blair issued their Q1 2026 EPS estimates for shares of Autolus Therapeutics in a report issued on Wednesday, April 23rd. William Blair analyst M. Phipps anticipates that the company will post earnings of ($0.27) per shareApril 27, 2025 | marketbeat.comAutolus Therapeutics confirms license of Aucatzyl issued by U.K. MHRAApril 26, 2025 | finance.yahoo.comUK approves Autolus leukemia therapy with conditionsApril 26, 2025 | investing.comAutolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)April 25, 2025 | globenewswire.comJPMorgan Chase & Co. Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)JPMorgan Chase & Co. lowered its position in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 16.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,071,533 shares of the company's stock after selling 213,175 shApril 25, 2025 | marketbeat.comEversept Partners LP Sells 307,663 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)Eversept Partners LP decreased its stake in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 75.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 98,895 shares of the company's stock after selling 307,663April 24, 2025 | marketbeat.comAutolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor EventApril 23, 2025 | finance.yahoo.comAutolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor EventApril 23, 2025 | globenewswire.comAvoro Capital Advisors LLC Trims Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)Avoro Capital Advisors LLC cut its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 19.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,910,642 shares of the company's stock after selling 2,435,0April 23, 2025 | marketbeat.com Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address AUTL Media Mentions By Week AUTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUTL News Sentiment▼0.410.56▲Average Medical News Sentiment AUTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUTL Articles This Week▼84▲AUTL Articles Average Week Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arrowhead Pharmaceuticals News Today Denali Therapeutics News Today Twist Bioscience News Today Vericel News Today Kiniksa Pharmaceuticals News Today Agios Pharmaceuticals News Today Sarepta Therapeutics News Today Recursion Pharmaceuticals News Today Apogee Therapeutics News Today IDEAYA Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUTL) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUTL Stock Free AUTL Stock Alerts